Captopril reduced all-cause mortality by 19% and heart failure progression by 22% in post-MI patients with left ventricular dysfunction, and lowered blood pressure by 10–20 mmHg systolic and 5–15 mmHg diastolic in hypertension patients.
Captopril is an effective, short-acting ACE inhibitor for managing hypertension, heart failure, post-MI LV dysfunction, and diabetic nephropathy, though it has been largely replaced by longer-acting agents in many clinical settings.
Effect estimate: 19% reduction in all-cause mortality post-MI (SAVE trial)
Captopril is an FDA-approved medication that plays an important regarding management of hypertension, left ventricular dysfunction post-myocardial infarction, and diabetic nephropathy. It is a key component in the therapy of these cardiovascular disorders since it mainly works by blocking the renin-angiotensin-aldosterone system (RAAS). By preventing the conversion of angiotensin I to angiotensin II, captopril effectively reduces the pathophysiological cascades that lead to hypertension and heart failure. This activity explains regarding captopril's mechanism of action, dosage considerations, pharmacodynamics, and monitoring strategies. Besides. captopril's off-label uses in acute hypertensive crises, and the Raynaud phenomenon will be discussed, equipping clinicians and inter professional team members along with essential knowledge to administer captopril. Understanding its adverse event profile and potential toxicities is essential for the safe and effective incorporation of captopril into clinical practice.
G. et al. (Thu,) conducted a review in Adults with hypertension, heart failure, post-myocardial infarction with left ventricular dysfunction, or diabetic nephropathy (n=11,000). Captopril vs. Conventional therapy such as diuretics, beta-blockers; placebo; other ACE inhibitors (e.g., enalapril, lisinopril) was evaluated on Cardiovascular morbidity and mortality, blood pressure reduction, left ventricular function improvement, proteinuria reduction in nephropathy (19% reduction in all-cause mortality post-MI (SAVE trial)). Captopril reduced all-cause mortality by 19% and heart failure progression by 22% in post-MI patients with left ventricular dysfunction, and lowered blood pressure by 10–20 mmHg systolic and 5–15 mmHg diastolic in hypertension patients.